Inhibition of prostate cancer-meditated osteoblastic bone lesions by the low-calcemic analog 1α-hydroxymethyl-16-ene-26,27-bishomo-25-hydroxy vitamin D3

Journal of Steroid Biochemistry and Molecular Biology

Volumn 97, Issue 1-2, 2005, Pages 203-211

  Peleg, Sara ^a   Khan, Farhana ^a   Navone, Nora M ^a   Cody, Dianna D ^a   Johnson, Evan M ^a   Van Pelt, Carolyn S ^a   Posner, Gary H ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

1,25 Dihydroxyvitamin D3; Osteoblasts; Prostate cancer bone metastases; Vitamin D analog

Indexed keywords

1ALPHA HYDROXYMETHYL 16 ENE 26,27 BISHOMO 25 HYDROXYVITAMIN D3; COLECALCIFEROL DERIVATIVE; JK 16262; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BONE MARROW CELL; BONE METASTASIS; CANCER CELL; CELL DIFFERENTIATION; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONTROLLED STUDY; CORTICAL BONE; EPIPHYSIS; HUMAN; MALE; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; PROSTATE CARCINOMA;

ANIMALS; CALCIFEDIOL; CALCIUM; CELLS, CULTURED; DISEASE PROGRESSION; MALE; MICE; MOLECULAR STRUCTURE; OSTEOBLASTS; PROSTATIC NEOPLASMS;

ANIMALIA;

EID: 27544488803     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2005.06.015     Document Type: Conference Paper

References (26)

1. E.D. Crawford Epidemiology of prostate cancer Urology 62 2003 3 12 (Review)
2. V.J. Assikis, and J.W. Simons Novel therapeutic strategies for androgen-independent prostate cancer: an update Semin. Oncol. 31 2004 26 32 (Review)
3. P. Mathew, I.J. Fidler, and C.J. Logothetis Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer Semin. Oncol. 31 2004 24 29 (Review)
4. G.B. Cook, and F.R. Watson Events in the natural history of prostate cancer: using salvage curves, mean age distributions and contingency coefficients J. Urol. 96 1968 87 96
5. K.S. Koeneman, F. Yeung, and L.W.K. Chung Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment Prostate 39 1999 246 261
6. 3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter J. Cell. Biochem. 89 2003 771 777
7. 3 suppresses the bone-related Runx2/Cbfa1 gene promoter Exp. Cell Res. 274 2002 323 333
8. D.M. Peehl, A.V. Krishnan, and D. Feldman Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer J. Nutr. 133 2003 2461S 2469S (Review)
9. S.E. Blutt, T.C. Polek, L.V. Stewart, M.W. Kattan, and N.L. Weigel A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice Cancer Res. 60 2000 779 782
10. R. Bouillon, W.H. Okamura, and A.W. Norman Structure-function relationships in the vitamin D endocrine system Endocr. Rev. 16 1995 200 257
11. S. Peleg, and G.H. Posner Vitamin D analogs as modulators of vitamin D receptor action Curr. Top. Med. Chem. 3 2003 1555 1572 (Review)
12. 3 without increasing its affinity to the vitamin D receptor J. Cell. Biochem. 63 1996 149 161
13. 3 and its A ring-modified analogs Mol. Endocrinol. 12 1998 525 535
14. 3. Synthesis and preliminary biological evaluation J. Med. Chem. 41 1998 3008 3014
15. G.H. Posner, H.B. Jeon, A. Sarjeant, E.S. Riccio, R.S. Doppalapudi, I.M. Kapetanovic, U. Saha, P. Dolan, and T.W. Kensler Low-calcemic, efficacious, 1alpha,25-dihydroxyvitamin D(3) analog QW-1624F(2)-2: calcemic dose-response determination, preclinical genotoxicity testing, and revision of A-ring stereochemistry Steroids 69 2004 757 762
16. N.M. Navone, M.C. Rodriquez-Vargas, W.F. Benedict, P. Troncoso, T.J. McDonnell, J.H. Zhou, R. Luthra, and C.J. Logothetis TabBO: a model reflecting common molecular features of androgen-independent prostate cancer Clin. Cancer Res. 6 2000 1190 1197
17. J. Yang, K. Fizazi, S. Peleg, C.R. Sikes, A.K. Raymond, N. Jamal, M. Hu, M. Olive, L.A. Martinez, C.G. Wood, C.J. Logothetis, G. Karsenty, and N.M. Navone Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway Cancer Res. 61 2001 5652 5659
18. K. Fizazi, J. Yang, S. Peleg, C.R. Sikes, E.L. Kreimann, D. Daliani, M. Olive, K.A. Raymond, T.J. Janus, C.J. Logothetis, G. Karsenty, and N.M. Navone Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts Clin. Cancer Res. 9 2003 2587 2597
19. S. Wei, S.L. Teitelbaum, M.W. Wang, and F.P. Ross Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors Endocrinology 142 2001 1290 1295
20. T.A. Guise, J.J. Yin, S.D. Taylor, Y. Kumagai, M. Dallas, B.F. Boyce, T. Yoneda, and G.R. Mundy Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis J. Clin. Invest. 98 1996 1544 1549
21. R.J. Thomas, T.A. Guise, J.J. Yin, J. Elliott, N.J. Horwood, T.J. Martin, and M.T. Gillespie Breast cancer cells interact with osteoblasts to support osteoclast formation Endocrinology 140 1999 4451 4458
22. J.M. Brown, E. Corey, Z.D. Lee, L.D. True, T.J. Yun, M. Tondravi, and R.L. Vessella Osteoprotegerin and RANK ligand expression in prostate cancer Urology 57 2001 611 616
23. Y. Lee, E. Schwarz, M. Davies, M. Jo, J. Gates, J. Wu, X. Zhang, and J.R. Lieberman Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone J. Orthop. Res. 21 2003 62 72
24. S. Peleg, M. Uskokovic, A. Ahene, B. Vickery, and Z. Avnur Cellular and molecular events associated with the bone-protecting activity of the noncalcemic vitamin D analog Ro-26-9228 in osteopenic rats Endocrinology 143 2002 1625 1636
25. 3 (Ro-26-9228) Mol. Endocrinol. 18 2004 874 887
26. 3 into new metabolites with significant biological activity: studies in rat osteosarcoma cells (UMR 106 and ROS 17/2.8) J. Cell. Biochem. 82 2001 599 609